After spending the last 10-plus years in court, Illumina and BGI Group have reached a $325 million settlement to resolve a number of patent and antitrust claims across the US centered around the companies’ DNA sequencing technology.
Illumina is forking over the $325 million to settle claims following two recent jury decisions in Delaware and California, as well as an antitrust case in California, according to a statement on Thursday from MGI Tech, a BGI affiliate.
As part of the deal, each party will drop any challenges to the California and Delaware jury decisions, and Illumina gets a license to the family of patents that BGI asserted in Delaware.
In 2010, Illumina filed a complaint in California against Complete Genomics, an MGI subsidiary, alleging that the company infringed on three of its DNA sequencing patents with the latter company’s “Complete Genomics Analysis Platform.” In response, Complete Genomics asserted that Illumina had “attempted to achieve monopoly power in genome sequencing technology.”
In a later Delaware case, Complete Genomics accused Illumina of infringing on its own patents with “two-channel” sequencing systems, kits to prepare DNA fragments for sequencing and kits to immobilize, amplify and sequence fragments. The company also filed an anticompetitive suit against Illumina in Delaware last year.
Back in November, a federal jury ruled that four of Illumina’s five patents in the California case were valid, awarding it $8 million, according to a Law360 report. But in May, a Delaware jury decided that Illumina owes Complete Genomics more than $333 million for infringing on two patents, court documents state.
This latest settlement should put an end to the storm of lawsuits — at least for a while. According to MGI’s statement:
“The parties also agree to a three-year period of peace with respect to claims of U.S. patent infringement and violations of any antitrust or unfair competition laws of the United States, during which time they will not sue each other or respective customers in the United States or accrue liability for existing platforms.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI